Numerous studies have sought to predict the response to immunotherapy by measuring biomarkers such as PD‐L1 expression, tumor mutational load, and T cell repertoire sequencing7, 8, 9; however, recent studies have shown contrasting results.10 Here, CD274 is linked to neoplasm.